. Author manuscript; available in PMC: 2013 Nov 1.

Published in final edited form as: Cancer. 2012 Mar 20;118(21):5358–5365. doi: 10.1002/cncr.27528

Table 2.

Follow-up and Progression Status Summary

	NCCTG		SWOG

	NSCLC (n=660)	SCLC (n=116)	NSCLC (n=297)	SCLC (n=131)

Alive (%)	22.6%	6.9%	7.1%	3.8%

Follow-up Time in months for Alive Patients Median (Range)	1.0 (0.0-6.0)	1.5 (0.1-6.3)	3.7 (0.8-5.2)	2.2 (0.2-2.8)

*Progression Occurrences^, N (%)**
On Treatment	346 (66.5)	69 (66.3)	175 (78.1)	93 (86.9)
Long Term Follow-up	174 (33.5)	35 (33.7)	49 (21.9)	14 (13.1)

*Time in Months from Last Progression-free Scan to Disease Progression^ Median (Range)**
During Treatment	1.4 (0.1-4.1)	1.4 (0.3-3.1)	1.3 (0.03-13.1)	1.1 (0.0-2.1)
During Follow-up	3.0 (0.0-48.3)	3.0 (0.1-14.1)	1.7 (0.2-24.3)	1.3 (0.4-5.3)

Reported for patients who progressed; NCCTG NSCLC (n=520), NCCTG SCLC (n=104), SWOG NSCLC (n=123), SWOG SCLC (n=50).